OPRA Asthma & COPD MCQs 2027: Inhalers & Answers

Preparing for OPRA asthma and COPD MCQs in 2027? Understanding respiratory pharmacology, inhaler medications and the differences between asthma and chronic obstructive pulmonary disease (COPD) can help overseas-qualified pharmacists strengthen their pharmaceutical science knowledge.

Asthma and COPD affect the respiratory system, but their underlying disease mechanisms, treatment approaches and medication considerations are different.

Commonly used respiratory medicines include short-acting beta-2 agonists, long-acting bronchodilators, inhaled corticosteroids and muscarinic antagonists.

For the Overseas Pharmacist Readiness Assessment (OPRA), it is important to understand how these medicines work, their adverse effects and their role in safe medicine use.

This guide covers asthma and COPD pharmacology for OPRA 2027, including drug classifications, inhaler mechanisms, important safety considerations, current Australian guidance and 10 original practice MCQs with explanations.

Are Asthma and COPD Questions Included in the OPRA Exam?

Respiratory physiology and respiratory medicine concepts connect with several areas of the OPRA syllabus published by the Australian Pharmacy Council (APC).

The official examination assesses biomedical sciences, pharmacology, pharmacokinetics, pharmaceutical science and therapeutics.

The APC does not publish a separate asthma or COPD question weightage.

Candidates should therefore understand these topics within the broader syllabus rather than assume they will encounter a fixed number of respiratory questions.

Explore our Complete OPRA Exam Syllabus for the official subject-wise breakdown.

Asthma vs COPD: Important Differences for OPRA

Before studying respiratory medicines, understand the basic differences between asthma and COPD.

Asthma is a chronic inflammatory airway condition characterised by variable respiratory symptoms and variable airflow limitation.

COPD is a chronic respiratory condition involving persistent airflow limitation, commonly associated with exposure to tobacco smoke or other harmful particles and gases.

Both conditions require appropriate clinical assessment. Some people may also have features of both asthma and COPD.

For OPRA preparation, understand the disease mechanisms and why treatment approaches differ.

Important Asthma and COPD Drug Classes for OPRA 2027

A useful way to revise respiratory pharmacology is to classify medicines according to their mechanism of action.

The appropriate use of these medicines differs between asthma and COPD.

1. Short-Acting Beta-2 Agonists (SABA)

Short-acting beta-2 agonists are bronchodilators that relax airway smooth muscle.

Examples:

• Salbutamol

• Terbutaline

These medicines stimulate beta-2 adrenergic receptors, activating intracellular signalling pathways that increase cyclic AMP.

This contributes to relaxation of bronchial smooth muscle and widening of the airways.

Important adverse effects can include tremor, palpitations, tachycardia and a reduction in serum potassium, particularly with substantial systemic exposure.

Current Australian asthma guidance: SABA-only treatment is no longer the recommended approach for adults and adolescents with asthma. The Australian Asthma Handbook supports ICS-containing treatment, including appropriate anti-inflammatory reliever strategies.

This is particularly important because learning older treatment classifications without checking current recommendations can cause confusion.

OPRA revision tip: Understand the mechanism of beta-2 receptor stimulation and distinguish bronchodilation from control of airway inflammation.

2. Long-Acting Beta-2 Agonists (LABA)

Long-acting beta-2 agonists produce prolonged bronchodilation.

Examples include:

• Formoterol

• Salmeterol

These medicines act on beta-2 adrenergic receptors in airway smooth muscle.

Although both are long-acting bronchodilators, they differ in their onset of action.

Formoterol has a relatively rapid onset of bronchodilation, whereas salmeterol has a slower onset.

Important safety point: LABA monotherapy should not be used to manage asthma without appropriate inhaled corticosteroid treatment.

Certain prescribed ICS-formoterol combination inhalers can be used in specific anti-inflammatory reliever or maintenance-and-reliever regimens.

However, this does not mean every LABA inhaler can be used as an asthma reliever.

3. Inhaled Corticosteroids (ICS)

Inhaled corticosteroids are important anti-inflammatory medicines for asthma.

Examples include:

• Budesonide

• Beclometasone

• Fluticasone

ICS act through intracellular glucocorticoid receptors and influence gene transcription, reducing inflammatory signalling and the activity of several inflammatory pathways.

They help reduce airway inflammation and the risk of asthma exacerbations.

Unlike short-acting bronchodilators, inhaled corticosteroids do not provide the same immediate direct airway smooth-muscle relaxation.

Common Adverse Effects of ICS

Important local adverse effects include:

• Oropharyngeal candidiasis (oral thrush)

• Dysphonia or hoarse voice

• Throat irritation

Rinsing the mouth with water and spitting after using an ICS-containing inhaler can help reduce local adverse effects.

Using a suitable spacer with a compatible pressurised metered-dose inhaler may also reduce medicine deposition in the mouth and throat.

OPRA revision tip: Understand why inhaled corticosteroids help control inflammation and why correct inhaler technique matters.

4. Muscarinic Antagonists: SAMA and LAMA

Muscarinic antagonists reduce cholinergic-mediated bronchoconstriction.

They inhibit muscarinic receptors in airway smooth muscle, particularly M3 receptor-mediated effects.

Short-acting muscarinic antagonist (SAMA):

Ipratropium

Long-acting muscarinic antagonists (LAMA):

Tiotropium and umeclidinium

These medicines are important bronchodilator classes, particularly in COPD management.

Common adverse effects may include dry mouth.

Other anticholinergic effects may occur depending on the medicine, administration and systemic exposure.

5. Leukotriene Receptor Antagonists

Montelukast is an example of a cysteinyl leukotriene receptor antagonist.

Leukotrienes contribute to bronchoconstriction, mucus production and airway inflammation.

Montelukast blocks leukotriene-mediated signalling through the CysLT1 receptor.

It is not a rapid rescue medicine for acute bronchospasm.

Montelukast also has important neuropsychiatric safety warnings, including possible changes in mood, behaviour and sleep.

Candidates should understand both its mechanism and its safety considerations.

Asthma Treatment Principles: What Has Changed?

The Australian Asthma Handbook was updated in September 2025.

An important change was the recommendation against using a short-acting beta-2 agonist alone as asthma treatment for adults and adolescents.

The updated guidance supports ICS-containing treatment, including suitable anti-inflammatory reliever (AIR) and maintenance-and-reliever therapy (MART) approaches.

Understanding AIR and MART

Anti-inflammatory reliever (AIR): Uses an appropriate ICS-formoterol combination inhaler as a reliever to provide bronchodilation together with an inhaled anti-inflammatory medicine.

Maintenance-and-reliever therapy (MART): Uses a suitable ICS-formoterol inhaler for both scheduled maintenance treatment and symptom relief, according to the prescribed regimen.

Not all ICS/LABA combinations or inhaler devices are suitable for AIR or MART.

Specific products, indications and age restrictions must be checked in current guidance.

For OPRA preparation, candidates should understand the underlying pharmacological principle: combining rapid bronchodilation with anti-inflammatory therapy can address different aspects of asthma.

COPD Pharmacology: LABA, LAMA and ICS

COPD management differs from asthma management.

Long-acting bronchodilators, particularly LABA and LAMA medicines, are central components of maintenance therapy for many patients with COPD.

An ICS-containing regimen may be considered for selected patients based on clinical characteristics and exacerbation risk.

However, inhaled corticosteroids are not appropriate for every patient with COPD.

ICS treatment in COPD can also increase the risk of pneumonia in some patients.

The Australian COPD-X guidelines provide evidence-based recommendations for individualised treatment.

Important distinction: ICS-containing treatment is fundamental to current asthma management, while bronchodilator-focused therapy is central to COPD management, with ICS reserved for selected circumstances.

Inhaler Technique: An Important OPRA Patient-Care Concept

An inhaler's effectiveness depends partly on how correctly it is used.

Different inhaler devices require different breathing techniques.

Pressurised Metered-Dose Inhalers (pMDIs)

A pressurised metered-dose inhaler releases a measured amount of medicine when activated.

Patients generally need to coordinate device activation with slow inhalation unless using an appropriate spacer.

Spacers can simplify this process and improve delivery of medicine to the lungs.

Dry Powder Inhalers (DPIs)

Dry powder inhalers depend on the user's inspiratory effort to disperse the powder.

They generally require a stronger, more forceful inhalation than conventional pMDIs.

Patients should not exhale into a dry powder inhaler because moisture can interfere with the powder.

Why Inhaler Technique Matters

Incorrect inhaler technique may reduce medicine delivery to the lungs and contribute to poor disease control.

Pharmacists play an important role in checking inhaler technique and helping patients understand their prescribed devices.

The correct technique depends on the specific inhaler.

OPRA Asthma and COPD MCQs 2027: 10 Practice Questions With Answers

The following questions are independently created educational examples for OPRA preparation. They are not official or recalled APC examination questions.

Question 1: Salbutamol Mechanism

Which mechanism BEST explains the bronchodilator action of salbutamol?

A. Blockade of muscarinic M3 receptors
B. Activation of beta-2 adrenergic receptors
C. Inhibition of leukotriene synthesis
D. Direct inhibition of inflammatory gene transcription

Correct Answer: B. Activation of beta-2 adrenergic receptors

Explanation: Salbutamol stimulates beta-2 adrenergic receptors in airway smooth muscle, activating signalling pathways that promote bronchodilation.

Question 2: Inhaled Corticosteroids

Which statement BEST describes the primary therapeutic action of inhaled corticosteroids in asthma?

A. They directly inhibit bacterial protein synthesis
B. They immediately reverse all airway obstruction
C. They reduce airway inflammation
D. They block acetylcholine release from motor neurons

Correct Answer: C. They reduce airway inflammation

Explanation: ICS act through glucocorticoid receptor-mediated pathways to reduce inflammatory activity in the airways.

Question 3: LABA Safety

Which statement is CORRECT regarding LABA use in asthma?

A. LABA monotherapy is appropriate for all patients with asthma
B. LABAs should replace anti-inflammatory treatment entirely
C. All LABAs have identical onset times
D. LABAs should be used with appropriate ICS-containing treatment in asthma

Correct Answer: D. LABAs should be used with appropriate ICS-containing treatment in asthma

Explanation: LABA monotherapy without an inhaled corticosteroid is not an appropriate asthma management strategy. The correct combination and regimen depend on the patient and product.

Question 4: Muscarinic Antagonists

Tiotropium produces bronchodilation primarily by:

A. Blocking muscarinic receptors involved in airway constriction
B. Increasing histamine release
C. Stimulating beta-1 adrenergic receptors
D. Inhibiting bacterial cell-wall synthesis

Correct Answer: A. Blocking muscarinic receptors involved in airway constriction

Explanation: Tiotropium is a long-acting muscarinic antagonist that reduces cholinergic-mediated bronchoconstriction.

Question 5: Inhaled Corticosteroid Safety

Which counselling point may help reduce oropharyngeal candidiasis associated with an inhaled corticosteroid?

A. Increasing the inhaled dose without review
B. Rinsing the mouth with water and spitting after use
C. Using another person's inhaler
D. Exhaling into the inhaler mouthpiece before every dose

Correct Answer: B. Rinsing the mouth with water and spitting after use

Explanation: Rinsing and spitting after ICS use can help reduce residual medicine in the mouth and lower the risk of local adverse effects.

Question 6: Respiratory Pharmacology

Which medicine is classified as a leukotriene receptor antagonist?

A. Salbutamol
B. Budesonide
C. Montelukast
D. Tiotropium

Correct Answer: C. Montelukast

Explanation: Montelukast blocks cysteinyl leukotriene receptor signalling. It is not used to provide rapid relief of acute bronchospasm.

Question 7: COPD Pharmacology

Which medicine class is a central component of maintenance bronchodilator treatment for many patients with COPD?

A. Antifungal medicines
B. Long-acting bronchodilators such as LABA or LAMA
C. Oral antibiotics for every patient
D. Antihistamines as the sole maintenance treatment

Correct Answer: B. Long-acting bronchodilators such as LABA or LAMA

Explanation: Long-acting beta-2 agonists and muscarinic antagonists are important maintenance bronchodilator options in COPD.

Question 8: Inhaler Devices

Which statement BEST describes the inhalation technique generally required for a dry powder inhaler?

A. The patient should exhale directly into the device
B. The patient should use a spacer with every DPI
C. The device always delivers medicine without inhalation
D. The patient usually needs a sufficiently strong, deep inhalation to disperse the powder

Correct Answer: D. The patient usually needs a sufficiently strong, deep inhalation to disperse the powder

Explanation: Dry powder inhalers depend on inspiratory airflow for powder dispersion. The precise technique is device-specific.

Question 9: Beta-2 Agonist Adverse Effects

Which adverse-effect combination is associated with substantial systemic exposure to beta-2 agonists?

A. Tremor, tachycardia and hypokalaemia
B. Hearing loss and renal failure in every patient
C. Oral candidiasis and voice changes as the primary direct effects
D. Severe neutropenia in all patients

Correct Answer: A. Tremor, tachycardia and hypokalaemia

Explanation: Beta-2 receptor stimulation can produce skeletal muscle tremor, cardiovascular effects and increased cellular uptake of potassium.

Question 10: Asthma Management Principles

Under the Australian Asthma Handbook's 2025 guidance, which statement BEST describes maintenance of asthma care in adults and adolescents?

A. SABA-only treatment is preferred for all patients
B. Inhaled anti-inflammatory treatment has no role in preventing exacerbations
C. ICS-containing treatment is an important component of current asthma management
D. LABA monotherapy is recommended instead of all other inhaled treatments

Correct Answer: C. ICS-containing treatment is an important component of current asthma management

Explanation: The updated Australian Asthma Handbook emphasises ICS-containing treatment and advises against relying on SABA alone for adults and adolescents with asthma.

How to Prepare for OPRA Respiratory Pharmacology MCQs

A systematic approach can help you revise the main respiratory medicine classes and their effects.

Step 1: Understand Respiratory Physiology

Start with airway smooth muscle function, bronchoconstriction, gas exchange and inflammatory processes.

Step 2: Classify Respiratory Medicines

Group medicines into SABA, LABA, SAMA, LAMA, ICS and leukotriene receptor antagonists.

Step 3: Learn Their Mechanisms

Understand beta-2 receptor stimulation, muscarinic receptor blockade and glucocorticoid receptor-mediated anti-inflammatory effects.

Step 4: Compare Asthma and COPD

Study why ICS-containing therapy is important in asthma and why long-acting bronchodilators play a central role in COPD.

Step 5: Revise Adverse Effects and Inhaler Technique

Connect drug mechanisms with tremor, dry mouth, oral thrush and other relevant adverse effects.

Step 6: Practise Original MCQs

Attempt different types of questions and review the explanations behind incorrect answers.

Seven-Day OPRA Respiratory Pharmacology Study Plan

This is an independently suggested study timetable, not an official APC preparation plan.

Common Mistakes to Avoid

Confusing relievers with preventers: Understand whether a medicine primarily provides bronchodilation, reduces inflammation or performs both functions in an appropriate combination.

Assuming asthma and COPD have identical treatment approaches: Their underlying mechanisms and treatment priorities differ.

Ignoring current asthma guidelines: Older recommendations about SABA-only treatment may not reflect current Australian guidance.

Memorising drug names without mechanisms: Learn the relevant receptors and pharmacological effects.

Overlooking inhaler technique: Delivery devices and breathing technique affect how medicines reach the lungs.

Conclusion

Preparing for OPRA asthma and COPD MCQs in 2027 requires a clear understanding of respiratory physiology, medicine classifications, mechanisms of action and important safety considerations.

Focus on beta-2 agonists, muscarinic antagonists, inhaled corticosteroids and leukotriene receptor antagonists.

Understand how asthma and COPD differ and why treatment strategies are not interchangeable.

Review current evidence-based guidance, practise original MCQs and connect drug mechanisms with their effects on the respiratory system.

For comprehensive OPRA preparation, integrate respiratory pharmacology with the other content areas in the official APC examination blueprint.

Explore Free OPRA Preparation Resources

• Complete OPRA Exam Syllabus

• Free OPRA Sample Papers

• OPRA Readiness Quiz

• OPRA Exam Preparation Articles

Need help organising your OPRA studies? Request free OPRA preparation guidance through the enquiry form on OPRAExam.in.

The website provides independent educational resources and is not affiliated with APC.

Official References

1. Australian Pharmacy Council — OPRA Exam Guide

2. National Asthma Council Australia — Australian Asthma Handbook

3. National Asthma Council Australia — Asthma and COPD Medications

4. COPD-X — Australian and New Zealand COPD Guidelines

5. National Asthma Council Australia — Inhaler Technique

Last reviewed: 12 November 2026

Disclaimer: OPRAExam.in is an independent educational website and is not affiliated with or endorsed by the Australian Pharmacy Council. The practice questions are independently developed and are not official APC content. This article is for examination preparation only and is not intended to provide patient-specific treatment recommendations.